Xenex Disinfection Services Inc. — Cyborg Score 7/10

Strong
Healthcare Equipment & Disinfection Technology

Strategic Profile

Xenex's pulsed, high energy UV light technology is uniquely lethal to microorganisms – producing peaks 4300x more intense than a mercury lamp. The company works with 900+ prominent facilities including over 130 government facilities utilizing Xenex programs for pathogen deactivation.

Cyborg Score Rationale

Xenex demonstrates strong product-market fit with established adoption across 900+ healthcare facilities and differentiated UV disinfection technology. The company has experienced leadership with successful startup track records and solid investor backing, though limited public financial disclosure and private status constrain full visibility.

Top Insights

  • Founders Mark Stibich and Julie Stachowiak are Johns Hopkins epidemiologists who built the company to provide healthcare facilities a more effective approach to prevent pathogen transmission driven by scientific evidence
  • CEO Morris Miller co-founded and funded Xenex; he previously co-founded Rackspace Managed Hosting, which was brought private by Apollo for $4.3 billion
  • Xenex has 16 investors including Battery Ventures, RK Ventures, and Targeted Technology Fund II
  • The company has 51-200 employees as of recent data

Named Competitors

  • TOMI Environmental Solutions — Hydrogen peroxide vapor disinfection systems
  • American BioScience Inc. — Hospital disinfection and sterilization solutions
  • ClorDiSys Solutions — Chlorine dioxide disinfection technology

Recent Developments

  • (June 2024) Exhibited at AORN conference booth #2201 promoting LightStrike+ UV technology for operating rooms
  • (2026) Continued expansion of healthcare facility partnerships and product innovation initiatives

Open the full interactive Xenex Disinfection Services Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →